DT 2219ARL

Drug Profile

DT 2219ARL

Alternative Names: Anti-CD19-anti-CD22-diphtheria-toxin-fusion-protein; DT-2219ARL; DT2219; IND100780; OXS 1550

Latest Information Update: 25 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Minnesota
  • Class ADP ribose transferases; Antineoplastics; Bispecific antibodies; Drug conjugates; Immunotoxins; Recombinant fusion proteins
  • Mechanism of Action Immunomodulators; Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II B cell lymphoma; Leukaemia

Most Recent Events

  • 18 Apr 2017 Phase-II clinical trials in B-cell lymphoma (Second-line therapy or greater) in USA (IV) (NCT02370160)
  • 18 Apr 2017 Phase-II clinical trials in Leukaemia (Second-line therapy or greater) in USA (IV) (NCT02370160)
  • 31 Mar 2017 Oxis Biotech has patent protection for DT 2219ARL covering methods and compositions for bi-specific targeting of cd19/cd22 in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top